System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Grzegorz Helbig is an expert in Hematology at Medical University of Silesia (Poland). As of October 2026, ScienceLeadR ranks Grzegorz Helbig in the top 1% of experts in Poland for Eosinophilia and Leukemia. Grzegorz Helbig has authored 245 publications, the most recent in 2026, and is an investigator in 16 clinical trials, 6 of them ongoing. SLR score: 978 (community average: 125). How the SLR is computed.

LeadR Profile

Grzegorz Helbig Medical University of Silesia Poland
978 ScienceLeadR Reputation 978

Unlock

Register Login
Network Map

Hematology

Subspecialties: Transplantation - Oncology - Surgery

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2004 - 2026
Source: PubMed

Medical University of Silesia

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 245

Citations

Citations: 2 328 1st author: 62 Last author: 54 Unique author: 7

Main journals

Blood 31
Acta Haematologica Polonica 29
Ann Hematol 10
Bone Marrow Transplant 9
Am J Hematol 8

Best Journals

N Engl J Med 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Survival after hematopoietic cell transplantation in children and adults in four decades of experience: nationwide study.
PMID 42877690 — cells, immune system diseases, transplants, cell transplantation, transplantation, child, survival rate		Front Immunol20260
A Comparison of Outcomes in Patients with Secondary Acute Promyelocytic Leukemia (APL) and De Novo APL-A Case-Matched Retrospective Analysis of the Polish Adult Leukemia Group (PALG).
PMID 42794865 — radiotherapy, leukemia, promyelocytic, acute, leukemia, therapeutics		Cancers (Basel)20260
Haematopoietic stem cell transplantation in hepatosplenic T-cell lymphoma: a retrospective analysis of the EBMT Lymphoma Working Party.
PMID 42594932 — cells, mortality, microscopy, electron, scanning transmission, progression-free survival, incidence, lymphoma, stem cells, therapeutics, cell transplantation, stem cell transplantation, t-lymphocytes, transplantation, lymphoma, t-cell		Lancet Haematol20260
Allogeneic hematopoietic cell transplantation for myelodysplastic syndromes harboring a paroxysmal nocturnal hemoglobinuria clone-a study on behalf of the Chronic Malignancies and Severe Aplastic Anemia Working Parties of the EBMT.
PMID 42595842 — cells, anemia, aplastic, myelodysplastic syndromes, anemia, bone marrow transplantation, hemoglobinuria, cell transplantation, clone cells, transplantation		Bone Marrow Transplant20260
Autologous haematopoietic stem cell transplantation in standard-risk T-cell acute lymphoblastic leukaemia/lymphoma with negative residual disease status.
PMID 42540449 — cells, microscopy, electron, scanning transmission, lymphoma, stem cells, cell transplantation, stem cell transplantation, t-lymphocytes, transplantation		Arch Med Sci20260

Clinical Studies 16

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 3 8
Phase 2 5
N/A 1
Phase 1 1
Phase 4 1

By status:

Recruiting 5
Completed 4
Unknown 4
Terminated 2
Not yet recruiting 1

By type:

Interventional 15
Observational 1

By Monocentric/Multicentric:

monocentric 1
multicentric2to4 0
multicentric5to9 5
multicentricup10 10

Main Topics

Ongoing Clinical Trials

6 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
MAGIC AML Multiarm Multicenter RAndomized Molecularly GuIded Controlled Trial of Personalized Treatment Strategy of Acute Myeloid Leukemia
2023-503394-37-00 — magic, cytarabine, leukemia, leukemia, myeloid, acute, leukemia, myeloid, cladribine, daunorubicin, therapeutics, cytosine		Phase 3Recruiting2024
A phase 3 multicenter randomised prospective open label trial of fixed duration (12 cycles) venetoclax obinutuzumab vs fixed duration (15 cycles) venetoclax pirtobrutinib vs MRD guided venetoclax pirtobrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL) small lymphocytic lymphoma (SLL) aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes (CLL18 MOIRAI)
2023-510294-34-00 — research design, lymphoma, leukemia, lymphocytic, chronic, b-cell, duration of therapy, leukemia, leukemia, lymphoid, therapeutics, random allocation		Phase 3Recruiting2025
Registry and clinical trial comparing standard intensity and reduced intensity treatment in patients with AML or CLL who do not have residual disease
2024-512503-39-00 — registries, myelodysplastic syndromes, induction chemotherapy, lymphoma, leukemia, lymphocytic, chronic, b-cell, classification, leukemia, recycling, drug therapy, leukemia, myeloid, acute, leukemia, lymphoid, leukemia, myeloid, therapeutics, random allocation, chemotherapy		Phase 4Recruiting2025
A study to investigate the effect of adding bleximenib to standard of care treatment with intensive chemotherapy in patients with a specific type of acute myeloid leukemia (AML)
2025-522767-15-00 — leukemia, drug therapy, leukemia, myeloid, acute, maintenance, leukemia, myeloid, therapeutics, chemotherapy		Phase 3Not yet recruiting2026
Phase 1 trial of trametinib and gilteritinib for the treatment of relapsed or refractory acute leukemia patients
2024-518301-18-00 — leukemia, therapeutics		Phase 1Recruiting2022

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS